| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14740338.4.3.473 |
| P698 | PubMed publication ID | 15934854 |
| P50 | author | Fabio Vistoli | Q55345435 |
| Romano Danesi | Q67479522 | ||
| Piero Marchetti | Q37382607 | ||
| P2093 | author name string | Mario Del Tacca | |
| Massimiliano Barsotti | |||
| Ugo Boggi | |||
| Franco Mosca | |||
| Gabriella Amorese | |||
| Marco Del Chiaro | |||
| Gaetano Rizzo | |||
| Stefano Signori | |||
| P2860 | cites work | Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil | Q44339726 |
| Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol | Q44366730 | ||
| Basiliximab plus low-dose cyclosporin vs. OKT3 for induction immunosuppression following renal transplantation | Q44517184 | ||
| Non-cardiogenic pulmonary edema during basiliximab induction in three adolescent renal transplant patients | Q44531833 | ||
| Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. | Q44577546 | ||
| ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results | Q44608577 | ||
| Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation | Q44651731 | ||
| Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation | Q44662215 | ||
| Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year | Q44707789 | ||
| Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial | Q44765902 | ||
| Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. | Q44794104 | ||
| Basiliximab in association with tacrolimus and steroids in caucasian cadaveric renal transplanted patients: significant decrease in early acute rejection rate and hospitalization time | Q44796561 | ||
| Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation | Q44935457 | ||
| Medical and surgical aspects of pediatric renal transplantation using living donors | Q44976412 | ||
| Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials | Q47242957 | ||
| Safe administration of a humanized murine antibody after anaphylaxis to a chimeric murine antibody. | Q51692902 | ||
| A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluations. | Q52029967 | ||
| Constructing a prediction interval for time to reach a threshold concentration based on a population pharmacokinetic analysis: an application to basiliximab in renal transplantation. | Q52136678 | ||
| Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction | Q57371171 | ||
| Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials | Q30725010 | ||
| Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy | Q34094929 | ||
| Signaling domains of the interleukin 2 receptor | Q34252892 | ||
| Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies | Q34546358 | ||
| Reducing adverse effects of immunosuppressive agents in kidney transplant recipients | Q34547749 | ||
| A benefit-risk assessment of basiliximab in renal transplantation. | Q35626337 | ||
| New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis | Q35691924 | ||
| Uremia as a State of Immune Deficiency | Q39767280 | ||
| Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection | Q41155370 | ||
| Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts | Q42670216 | ||
| Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. | Q42679476 | ||
| An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation | Q43592410 | ||
| Economic analysis of basiliximab in renal transplantation | Q43660951 | ||
| Efficacy and tolerability of interleukin-2 receptor blockade with basiliximab in pediatric renal transplant recipients | Q43687549 | ||
| Basiliximab induction improves the outcome of renal transplants in children and adolescents. | Q43712111 | ||
| Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients | Q43828434 | ||
| CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab in cadaveric kidney transplantation | Q43828442 | ||
| Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation | Q43828444 | ||
| Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab | Q43828451 | ||
| Simulect, Neoral, Cellcept, and prednisone in kidney recipients with delayed graft function: a prospective controlled study | Q43828689 | ||
| Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection | Q43843796 | ||
| Single centre experience with basiliximab in paediatric renal transplantation | Q43867643 | ||
| Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation | Q44053836 | ||
| Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients | Q44101569 | ||
| Inhibition of the IL-15 pathway in anti-CD25 mAb treated renal allograft recipients | Q44104890 | ||
| Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine | Q44221070 | ||
| Early experience with simulect (basiliximab) induction in living donor renal allografting in India | Q44319149 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 473-490 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Efficacy and safety of basiliximab in kidney transplantation | |
| P478 | volume | 4 |
Search more.